Valneva shares at the bottom of the SBF 120, down 18.5% over three months
The Lyon-based vaccine maker ranks at the bottom of its index while the Paris market remains stable mid-session. The stock extends a decline that began several weeks ago and remains far from its medium- and long-term benchmarks.
A stock at the bottom of the ranking, far from its moving averages
Valneva shares fell 1.92% to €2.50 at midday, while the SBF 120 gained 0.02%. This decline places the stock among the largest decliners in the index. The stock remains below its three moving averages: the gap is 0.71% with the MM20 (€2.52) and 11.59% with the MM200 (€2.83).
Over three months, the loss reaches 18.55%, compared with 3.44% over the week. The decline occurs in a session where the Paris market remains calm, with the 10-year OAT at 4.91% and a 1.56-point spread with the Bund remaining benchmarks watched for French debt. The previous day's pullback below the MM50 thus continues without any notable rebound.
Results for the first nine months expected on November 24
Valneva will publish its results for the first nine months of 2026 on November 24. At the release of the first-half 2026 results on August 13, the company had confirmed its outlook for the year despite the persistent impact of the geopolitical context on travel.
Among the risks cited on that occasion was the dependence on deliveries of IXIARO to the U.S. Department of Defense, whose timing remains uncertain.
The group also mentioned regulatory decisions expected within the following twelve months on its candidate against Lyme disease.
Over one month, the stock remains nearly stable (-0.67%), while the data on the duration of response to the Ixchiq vaccine, published on November 10, did not reverse the three-month trend. The support at €2.33 and the resistance at €2.68 frame the current trading range.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorPharmacie et biotechnologies›Pharmacie, vaccins et santé animale
Context
Period
Period: S1 2026
Key reported figures
Revenue: 65,8 millions d'euros
Quarterly revenue: 65,8 millions d'euros
Revenue growth: -32,6 %
EBITDA: -39,8 millions d'euros
EBITDA margin: -60,4 %
Net income: -63,3 millions d'euros
Guidance from the release
Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
Expected revenue: 147,5 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.